Key considerations choice of antimicrobial agents Dr Andrew Seaton
|
|
- Gabriel Marvin Phillips
- 5 years ago
- Views:
Transcription
1 Key considerations choice of antimicrobial agents Dr Andrew Seaton
2 Key Considerations choice of antimicrobial agents and managing the IV to oral switch R. Andrew Seaton NHS Greater Glasgow and Clyde, Scotland, UK
3 Disclosures Consultancy/ advisory or lectures for Novartis (Daptomycin), Pfizer (Linezolid), Astellas (Fidaxomycin), Astrazeneca (Ceftaroline) Principle Investigator: OVIVA study, EuCORE registry (Novartis sponsored) Council member British Society of Antimicrobial Chemotherapy, Co-Chair BSAC OPAT Standing Committee, Member Scottish Antimicrobial Prescribing Group, Chair Antimicrobial Utilisation Committee and Lead Antimicrobial Management Team, NHS GGC
4 The Dilemma of OPAT Potential conflict between the choice of the most effective and narrow spectrum agent and the need for convenience in dosing and administration. Antibiotic selection should be based on appropriate prescribing principles rather than purely dosing convenience Howden Grayson, Med J Aus 2002; 176: 440
5 OPAT Outcomes OPAT is different from traditional modes of Rx: community based oral therapy/ inpatient based IV therapy Outcome of both infection and process is important: the infection (cure, improvement, failure) the process (readmission, adverse events) Choice of antimicrobial agent may influence infection and process outcome HAI risk (probably) less Is it appropriate to transpose IP practice into OPAT setting? Complex dosing regimens may delay discharge
6
7 Good Practice Recommendations 3.2 The treatment plan is the responsibility of the OPAT infection specialist, following discussion with the referring clinician. It should include choice and dose, frequency and duration. Should take into account flexibility based on clinical response 3.3 Antimicrobial choice within OPAT should be subject to review by the local antimicrobial stewardship programme
8 Good Practice Recommendations 4.1 Patients with superficial skin and soft tissue infection should be reviewed daily by the OPAT team to optimize speed of intravenous to oral switch.
9 Antimicrobial Stewardship in OPAT: What is reasonable? Use narrowest spectrum agents within limitations of OPAT Don t use IV therapy when oral therapy would suffice SSTI ; Timely IVOST BJI; Trend towards shorter IV Rx, OVIVA study Avoid prolonged antibiotic therapy as an alternative to proper source control Engagement with local Antimicrobial Stewardship programme
10 Antimicrobial Considerations in OPAT Is there an evidence base for the use of the agent for the condition (in OPAT)? Are there any specific safety or monitoring requirements? Is there a convenient ambulatory dosing regimen? The ideal OPAT agent is one that optimises outcome, minimises adverse events and is patient focussed with minimal inconvenience
11 PK / PD Principles Acknowledgement: Fiona Robb
12 OPAT Evidence 2 RCTs of OPAT: 1999 (n=100, variety) and 2004 (n=200, SSTI). Mainly Cefazolin BD RCTs of new antimicrobials includes OPAT Rx pts Corwin et al BMJ doi /bmj EB; Board et al Aust N Z J Public Health 2000; 24:305
13 Proportion of patients, % OPAT* in clinical trials: Complicated S. aureus bacteraemia 52% received OPAT (mean 14.9 days (1-49)) 100 P< P< OPAT (n=103) IPAT (n=97) P=0.061 P= MRSA IE Completed Success Rehm S et al. J Antimicrob Chemother 2009;63: Deaths Readmission SAE ***Daptomycin or vancomycin or semi-synthetic penicillin
14 Distribution of patients within the Glasgow OPAT service ( ) a. OPAT patient episodes b. OPAT days Seaton and Barr, EJIM, 2013
15 Trends over 10 yrs Trend over time Referral from non-local hospital X 2 trend = Referral from secondary care X 2 trend = Co-morbidity X 2 trend = Non-SSTI infection X 2 trend = MRSA infections (as % of S. aureus) X 2 trend = G-ve infections (% of +ve cultures) X 2 trend = Self / carer antibiotic admin X 2 trend = p < p < p < p < p = p = p < Barr et al, IJAA 2012
16 Antibiotic agents used for OPAT Most frequently used antibiotic agents for OPAT (2279 episodes) Ceftriaxone Teicoplanin Other 29% 63%
17 Relative frequency of first line antimicrobial agent use in Glasgow OPAT service. 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% SSTI BJI CVS Bacterae mia CNS UTI Abdo. Abscess other ertapenem daptomycin teicoplanin ceftriaxone SSTI = skin and soft tissue infection; BJI = bone and joint infection; CVS = cardiovascular system infections including endocarditis and intra-cardiac device infections; CNS = cardiovascular system infections; UTI = urinary tract infections; Abdo. Abscess = Intra-abdominal abscess including liver abscess. Seaton and Barr, EJIM, 2013
18 Note: An ADR in an individual patient in some instances involved multiple drug reaction types (e.g. rash and fever); each ADR type is counted separately in frequency bars even where they stem from one ADR event. Relative frequency of adverse drug reaction (ADR) types, in all first OPAT episodes over 10 year study period. Rash Severe gastro-intestinal Chills or fever Leucopenia, thrombocytopenia Nephrotoxicity Hepatotoxicity Nature of ADR unrecorded Other Anaphylactoid Frequency of ADR type
19 % with ADR ADRs, Infection Type and AB Used Daptomycin Ceftriaxone Teicoplanin
20 Ceftriaxone in OPAT
21 Duncan et al, Int J Clin Pharm DOI /s z
22 Duncan et al, Int J Clin Pharm DOI /s z
23 Duncan et al, Int J Clin Pharm DOI /s z
24 Clostridium difficile and OPAT 4 per 3,356 UK OPAT episodes (0.1%) 2 per 2,233 Glasgow OPAT episodes (0.05 events per 1000 OPAT patient days) Chapman et al JAC 2009; 64:1316 Mathews et al JAC 2007; 60: 356 Seaton et al IJAA 2011; 38: 243 Barr et al IJAA 2012; 39: 407
25 Teicoplanin in OPAT Indications 1 Resistant staphylococcal infections (CoNS or MRSA) Gram-positive infections with β-lactam allergy Failure with β-lactams Dosing regimen 2 Loading: mg/kg for 3 days (inpatient or outpatient) Maintenance: 3 /week (butterfly) TDM at longest interval (72 hours) Target trough concentration for deep-seated infections: μg/ml <20 μg/ml: increase dose or reduce interval (alt. days) >30 μg/ml: reduce dose or increase interval (2 or 1 /week) 1. Sanofi-aventis. Targocid (teicoplanin) Summary of Product Characteristics Lamont E et al. J Antimicrob Chemother 2009;doi: /jac/dkp147
26 Lamont E et al. J Antimicrob Chemother 2009;doi: /jac/dkp147
27 Lamont E et al. J Antimicrob Chemother 2009;doi: /jac/dkp147
28 OPAT Outcomes and Antimicrobial Agent used Infection outcome Process (OPAT) outcome 3 main patient groups Skin and soft tissue infection Bone and joint infection Endocarditis
29 Skin and Soft Tissue Infection
30 Patient group direction for SSTIs Patient group : non-life-threatening cellulitis amenable for home care and requiring i.v. therapy Uniform therapeutic management Suitable protocol in place Exclusions Prior physician review Indications for specialist review Indications for IVOST Trained, experienced staff Approved by ADTC IVOST, i.v. antibiotic oral switch therapy Seaton RA et al. J Antimicrob Chemother 2005;55:
31 OPAT treatment pathway for SSTIs: empiric antibiotic choice History of MRSA or Beta-lactam allergy? Yes Teicoplanin Clindamycin* *If Beta-lactam allergy or sensitive MRSA No Ceftriaxone Clindamycin or Flucloxacillin
32 Nurse-led Mx for OPAT SSTIs Comparison of patients pre- and post-introduction of a nurse-led management protocol Protocol management was associated with reduced duration of outpatient i.v. therapy (from 4 to 3 days, P=0.02) Seaton RA et al. J Antimicrob Chemother 2005;55:
33 Duration of OPAT (days) SSTI: Median duration of OPAT (days) Nurse-led IVOST Linear time trend in log (OPAT days) Estmate ( ) p< Year Seaton RA et al, IJAA, 2011
34 Common OPAT Antibiotics in SSTI No. Duration (days) Progression (%) Readmission (%) Significant AE OPAT failure* Ceftriaxone (2-4) Teicoplanin (3-12) *Switch of antibiotic, progression of infection or readmission Seaton RA et al, IJAA 2011
35 Factors Associated with OPAT Failure* in SSTI (n=963) Multiple logistic Regression Variable OR (95% CI) P value Age (per + 10 yrs) NS Female 1.65 ( ) MRSA NS Diabetes 2.02 ( ) Teico vs Ceftriaxone 1.87 ( ) *Switch of antibiotic, progression of infection or readmission Seaton RA et al, IJAA 2011
36 OPAT SSTI: Factors Associated with increase in duration of OPAT Multiple linear regression Variable Estimate* (95% CI) P value Age (per additional 10 years) 1.03 ( ) MRSA 1.47 ( ) Vascular disease 1.29 ( ) Teicoplanin vs Ceftriaxone 1.32 ( ) < Referred from community 0.91 ( ) Managed via PGD 0.71 ( ) < Infection type Bursitis vs cellulitis 1.81 ( ) < Wound infection vs cellulitis 1.74 ( ) Other infection vs cellulitis 1.25 (1.00, 1.56) * Estimates: percentage change in number of days in OPAT: for example, an estimate of 1.10 means that, on average, a variable is associated with a 10% increase in the number of days of treatment. Seaton RA et al, IJAA 2011
37 OPAT SSTI: Antibiotic therapy Nurse led IVOST effective and associated with reduced duration of IV Rx OPAT failure and Teicoplanin confounded by another variable? Teicoplanin less effective / more adverse events? Less subject to daily IVOST review therefore longer therapy? Alternative therapies when ceftriaxone contraindicated
38 Bone and joint Infection
39 Multivariate odds ratio of failing initial OPAT therapy Odds Ratio 95% C. I. P Diabetic foot infection MRSA infection CoNS/Diptheroids yrs Goodness of fit: log likelihood -66.5, r P= Mackintosh CL, White H.A, and Seaton R.A, JAC 2011
40 Kaplan-Meier survival estimate of time to treatment failure for all patients per diagnosis MWI VOM SA PK/PH/OM DFI analysis time (weeks) weeks Mackintosh CL, White H.A, and Seaton R.A, JAC 2011 number at
41 Hazard Ratio from Survival analysis (Cox regression) for the association of the initial IV Antibiotic with failure over the follow up period Initial IV Rx No. No. Failing Teicoplanin Hazard ratio Ceftriaxone Other 5 1 CI p
42 Endocarditis
43 OPAT Endocarditis Outcome Definitions OPAT failure (all OPAT episodes). Composite definition, any of: a) unplanned readmission or surgery during OPAT; b) adverse drug reaction leading to switch/readmission; and c) development of antibiotic resistance. Adverse Disease Outcome (ADO) (first OPAT episode). EXCLUDED: palliative intent cases; undetermined cause of death Definition of ADO: Endocarditis related death or suspected relapse at any time following OPAT completion / failure.
44 Baseline Characteristics: OPAT Endocarditis Characteristics of cohort 80 OPAT episodes (in 77 patients) Age in years, median (range) 60 (22 to 88) Male % Past medical history Previous episode of endocarditis % Adult congenital heart disease 7 8.8% Ischaemic heart disease % Cardiac failure % Chronic kidney disease % Immunosuppressive drugs % Current alcohol abuse 6 7.5% Site of infection Cardiac device related infection 4 5.0% Aortic valve % Prosthetic valve % Left sided % Septic emboli (pre-opat) %
45 Microbiology Microbiology N=80 % Viridans Streptococci % Oral Streptococci % Coagulase-negative Staphylococci % Methicillin sensitive S. aureus % No growth % Enterococcus 5 6.3% Mixed growth 3 3.8% MRSA 3 3.8% HACEK 2 2.5% Other 2 2.5% Unknown 1 1.3%
46 OPAT Antibiotics in Endocarditis Characteristics of OPAT procedures in cohort N = 80 Antimicrobial Ceftriaxone % Teicoplanin % Daptomycin % Flucloxacillin 4 5.0% Other 2 2.5%
47 Associations with OPAT failure Variable Failed n = 25 (31.3%) Completed n = 55 (68.7%) Multivariate analysis* OR CI P Cardiac failure or CKD 14 (63.6%) 8 (36.4%) Teicoplanin 12 (67.7%) 6 (33.3%) Specialist referral 17 (25.8%) 49 (74.2%) Also significant on univariate: Prosthetic valve, Median delay to IV start, per day (IQR), Glycopeptide-indicated organism, Implanted device, Streptococcal organism; ceftriaxone use. Not significant on univariate: Age; sex; other co-morbidities; S. aureus; left sided endocarditis; aortic valve endocarditis. *Logistic regression: stepwise backwards selection; factors retained in the model if P < 0.1. χ 2 = 30.3, full model 2 log likelihood = 63.6, P <
48 Reasons OPAT failure by antibiotic Endocarditis deterioration Other medical cause readmission Adverse drug reaction Venous catheter complication Antimicrobial resistance Unknown Teicoplanin (n=18) Ceftriaxone (n=45) Other (n=17)
49 Adverse Disease Outcome by prior OPAT failure Association of OPAT failure with subsequent Adverse Disease Outcome Hazard Ratio 4.78; p = (Log rank test)
50 OPAT and Endocarditis IE treated successfully in OPAT including some high risk features. History of cardiac or renal dysfunction may be unsuitable for OPAT, or require higher intensity monitoring. Increased risk of OPAT failure in Teicoplanin-treated patients, independent of microbiological aetiology and co-morbidity changed practice in Glasgow OPAT.
51 Frequency of first choice parenteral agent used in OPAT over 10 years (ceftriaxone and teicoplanin excluded). IM Penicillin preparation Daptomycin Ertapenem other combo Flucloxicillin Amikacin Non-antimicrobial Piperacillin-Tazobactam Meropenem or imipenem Amphoteracin B Anti-viral Amoxicillin or co-amoxiclav Gentamycin Vancomycin Ceftazadime Doxycycline Ben. Penicillin Colistin Frequency
52 Daptomycin in OPAT EuCORE study 550 (12%) of cohort Rx via OPAT over 5.5 yr period Prior AB Rx in 78% (48% prior Rx failure) SSTI, BJI, Prosthetic device-related and Endocarditis Concomitant Rx in 41%
53
54 28 days
55 Daptomycin-related adverse events in OPAT 15% AEs (86% mild/moderate) 9% ascribed to Daptomycin CPK increase in 1.5% Asthenia in 1.3% and Diarrhoea in 0.9% 3.1% discontinued CPK increase in 0.4% and Rhabdomyolysis in 0.4% 3.1% SAEs CPK/Rhabdomyolysis in 0.6% (all resolved) 2 deaths not related to Daptomycin
56 Ertapenem Carbapenem: Not Pseudomonas, Enterococci, Resistant G+ve infection ESBL infections Deep seated: First choice UTI: If no oral Rx possible (TMP, Nitrofurantoin, Pivmecillinam, Fosfomycin) Diabetic foot infection Intra-abdominal infection including liver abscess
57 Amikacin in OPAT Concentration dependent bactericidal activity Multi-drug resistant (MDR) mycobacterial infection inc. MDR-TB Alternative agent when drug toxicity or malabsorption Aminoglycoside of choice in NHS GGC Less susceptible to aminoglycoside inactivating bacterial enzymes Tuberculosis bacilli grow and multiply slowly Administer thrice weekly Therapeutic drug monitoring Adverse drug reactions Nephrotoxicity; monitor renal function weekly Ototoxicity; audiometry test every fortnight Acknowledgement: Fiona Robb
58 Current Amikacin Dosing Guidelines OPAT guidelines based on Peloquin et al 1,2 Outpatient 25 mg/kg three times weekly Amikacin concentration targets Outpatient Cmax mg/l Peloquin recommends 2 hr, 6 hr post dose and trough plasma concentrations In practice; weekly 1 hr post dose and trough plasma levels OPT; Pharmacokinetic parameter estimation programme MSc project has validated current practice 1. Peloquin C. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62: Peloquin C. Using Therapeutic Drug Monitoring to Dose the Antimycobacterial Drugs. Clinics in Chest Med 1997; 18: Acknowledgement: Fiona Robb
59 Meropenem in OPAT Eliminated via kidneys Renal impairment ( dose) Drug interactions Sodium valproate levels Bactericidal Inhibit bacterial cell wall synthesis (PBPs) In vitro PK/ PD data Exhibits T > MIC Some concentration dependent killing Post antibiotic effect Acknowledgement: Fiona Robb
60 Meropenem in OPAT Bronchiectasis patients Persistent/progressive lung condition Intermittent infective exacerbations with increasingly resistant organisms e.g. pseudomonas spp Meropenem 3g IV once daily 1, 2 Ensure T > MIC at least 40% of dosing interval Cmax/MIC for SPC doses only 2.5 hrs PAE for gram -ve bacteria 1. Darley ESR. Use of meropenem 3g once daily for outpatient treatment of infective exacerbations of bronchiectasis. JAC 2000; 45: Bowker KE. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. JAC 1996; 38: Acknowledgement: Fiona Robb
61 Meropenem in OPAT MIC 0.5 mg/l correlates best with efficacy Acknowledgement: Fiona Robb
62 Independent Risk Factors for Line Complications during OPAT OR P value Line Infection Increasing duration of OPAT (44 vs 38 days) Other line events Flucloxacillin vs other Tunnelled Central line vs Midline PICC vs midline Barr, et al EJClinMicroID, 2012
63 Conclusions Antimicrobial Stewardship important in OPAT but possibly not entirely translatable from IP practice IVOST for SSTI important and will reduce unnecessary exposure to IV Rx Emerging evidence for other infections should be taken into account
64 Conclusions Ceftriaxone and Teicoplanin commonly used OPAT agents Teicoplanin associated with increase in OPAT failure in SSTI, Endocarditis and trend in BJI Daptomycin and Ertapenem emerging role in OPAT in variety of infections Increase in OPAT Rx G-ve infections will demand greater diversity of agents used eg Meropenem, Amikacin Role of infusion devices...
65 Acknowledgements OPAT Nurses: Lindsay Semple, Claire Vallance, Deepa Matthew, Emma Sharp Antimicrobial Pharmacist: Fiona Robb OPAT Medics past and present: David Barr, Chris Duncan, Claire Mackintosh
66 Current Practice: Gram Positive Infections INFECTION AGENT DOSE COMMENT Cellulitis/ SSTI Ceftriaxone Teicoplanin Daptomycin Ertapenem 1-2 g OD Variable dose 4-6mg/kg 1g OD Review daily: Oral switch Clinda/ fluclox/ Linezolid Bone/Joint infection Daptomycin 6-8mg/kg + Oral RIF or Sodium Teicoplanin 15-20mg/Kg 3 xs / fusidate or Doxy week Staph aureus bacteraemia Ceftriaxone 2g OD Daptomycin 6-8mg/Kg +/- RIF Ceftriaxone Endocarditis Daptomycin 8-10mg/kg +/- RIF Ceftriaxone 2g 2g OD
67 Current Practice: Gram Negative Infections INFECTION AGENT DOSE COMMENT UTI Ertapenem 1g OD Oral Rx: TMP, Nitrofurantoin, Amikacin 15mg/kg OD Pivmecillinam, Fosfomycin Enteric fever Ceftriaxone 2g OD Azithromycin Intra-abdominal Sepsis / Liver abscess Ertapenem 1g OD Mycobacterial Amikacin 25mg/kg 3xs/week (M)DRGNB Pip-Taz, Meropenem, Colistin, Amikacin, Meropenem In combination Rx
Gram-Positive Infections and OPAT:
Gram-Positive Infections and OPAT: Developments and Observations R. Andrew Seaton Gartnavel General Hospital Glasgow, Scotland, UK The views presented are the views of the speaker and not necessarily the
More informationConsider the patient, the drug and the device how do you choose?
Consider the patient, the drug and the device how do you choose? Tim Hills Lead Pharmacist Antimicrobials and Infection Control Nottingham University Hospitals NHS Trust OPAT Recommendations Drug Therapy
More informationRole of IV Therapy in Bone and Joint Infection
Role of IV Therapy in Bone and Joint Infection Andrew Seaton ID Consultant, Queen Elizabeth University Hospital Lead Doctor Antimicrobial Management Team, NHS GGC @raseaton66 OPAT The IVnOAT Perspective
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationIntro Who should read this document 2 Key practice points 2 Background 2
Antibiotic Guidelines: Obstetric Anti-Infective Prescribing Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Kelly Alexander / Frances Garraghan
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationPharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care
Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationAntibiotic Management of Prosthetic Joint Infections
Antibiotic Management of Prosthetic Joint Infections R Andrew Seaton Consultant Infectious Diseases and General Medicine NHS Greater Glasgow and Clyde Declarations of interest Consultancy Novartis Pfizer
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationSepticaemia Definitions 1
Septicaemia Definitions 1 Term Definition Bacteraemia Systemic Inflammatory response (SIRS) Sepsis Bacteria that can be cultured from the blood stream The systemic response to a wide range of stresses.
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationMeropenem for all? Midge Asogan ICU Fellow (also ID AT)
Meropenem for all? Midge Asogan ICU Fellow (also ID AT) Infections Common reason for presentation to ICU Community acquired - vs nosocomial - new infection acquired within hospital environment Treatment
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationTreating Multi-drug Resistant Gramnegative. Fiona Robb Antimicrobial Pharmacist NHS Greater Glasgow & Clyde 9 th December 2016
Treating Multi-drug Resistant Gramnegative Infections in OPAT Fiona Robb Antimicrobial Pharmacist NHS Greater Glasgow & Clyde 9 th December 2016 Overview To describe the emerging threat of Antimicrobial
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 09:00 09:20 Registration
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 Time Topic/Activity
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More informationEmpiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital
Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationWho should read this document? 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version? 3
Neurosurgical infections (adult only) Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationCME Infectious diseases
Clinical Medicine 2013, Vol 13, No 5: 495 9 CME Infectious diseases Edited by Dr Gavin Barlow, consultant physician and honorary senior lecturer, Department of Infection and Tropical Medicine, Hull and
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationGrey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report to 214 Table of Contents I. Introduction..
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationThis survey was sent only to EIN members with a pediatric infectious diseases practice.
Infectious Diseases Society of America Emerging Infections Network Report for Query: Pediatric Outpatient Parenteral Antibiotic Therapy (OPAT) Overall response rate: 188/281 (66.9%) physicians responded
More informationThe role of oral antibiotics in Prosthetic joint infection. Matthew Dryden MD
The role of oral antibiotics in Prosthetic joint infection Matthew Dryden MD Persistence of bone infection Osteomyelitis in 1930 Prosthetic joint replacement demand is increasing When things go wrong Patient
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationAntimicrobial therapy in critical care
Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationPVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust
PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationCellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018
Cellulitis Assoc Prof Mark Thomas Conference for General Practice Auckland Saturday 28 July 2018 Summary Cellulitis Usual treatment flucloxacillin for 5 days Frequent recurrences consider penicillin 250mg
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationIntroduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.
Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationOutpatient parenteral antimicrobial treatment. Which antibiotics can be used?
Outpatient parenteral antimicrobial treatment Which antibiotics can be used? Franky Buyle SBIMC-BVIKM March 30th 2017 Brussels Pharmacy Multidisciplinary Infection Team Ghent University Hospital, Belgium
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More information